Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.39)
# 357
Out of 4,667 analysts
251
Total ratings
65.68%
Success rate
11.67%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Upgrades: Equal-Weight | $33 → $53 | $49.90 | +6.21% | 9 | Nov 14, 2024 | |
| UNH UnitedHealth Group | Maintains: Overweight | $615 → $610 | $600.50 | +1.58% | 15 | Oct 16, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $12 → $6 | $3.56 | +68.54% | 16 | Jun 28, 2024 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $7.22 | +38.50% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $4.31 | +27.61% | 9 | Nov 10, 2023 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $220 → $205 | $187.90 | +9.10% | 19 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $17.00 | -55.88% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $11.95 | +0.42% | 8 | Aug 30, 2023 | |
| CNC Centene | Downgrades: Equal-Weight | $94 → $73 | $59.10 | +23.52% | 10 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $161.32 | -10.12% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $260 | $237.85 | +9.31% | 14 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $294.64 | +23.88% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $621.14 | -32.38% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $7.84 | +1,430.61% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $293.97 | +110.91% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $397.48 | +25.79% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $56.83 | +118.19% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $323.39 | -1.67% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $120.34 | -41.83% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $43 → $39 | $8.24 | +373.30% | 15 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $135 | $59.00 | +128.81% | 8 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $194.38 | +0.32% | 6 | Oct 21, 2020 |
Doximity
Nov 14, 2024
Upgrades: Equal-Weight
Price Target: $33 → $53
Current: $49.90
Upside: +6.21%
UnitedHealth Group
Oct 16, 2024
Maintains: Overweight
Price Target: $615 → $610
Current: $600.50
Upside: +1.58%
Accolade
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $12 → $6
Current: $3.56
Upside: +68.54%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $7.22
Upside: +38.50%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $4.31
Upside: +27.61%
Charles River Laboratories International
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $220 → $205
Current: $187.90
Upside: +9.10%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $17.00
Upside: -55.88%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $11.95
Upside: +0.42%
Centene
Aug 30, 2023
Downgrades: Equal-Weight
Price Target: $94 → $73
Current: $59.10
Upside: +23.52%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $161.32
Upside: -10.12%
Aug 3, 2023
Maintains: Overweight
Price Target: $285 → $260
Current: $237.85
Upside: +9.31%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $294.64
Upside: +23.88%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $621.14
Upside: -32.38%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $7.84
Upside: +1,430.61%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $293.97
Upside: +110.91%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $397.48
Upside: +25.79%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $56.83
Upside: +118.19%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $323.39
Upside: -1.67%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $120.34
Upside: -41.83%
Jul 6, 2022
Maintains: Underweight
Price Target: $43 → $39
Current: $8.24
Upside: +373.30%
Feb 3, 2021
Maintains: Overweight
Price Target: $115 → $135
Current: $59.00
Upside: +128.81%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $194.38
Upside: +0.32%